David Durantel

The paper introduces ddOTs, a ddPCR method to quantify overlapping HBV transcripts, enabling precise analysis of cccDNA-driven transcription and RNA stability.

This study evaluates a liver-targeted TLR1/2 agonist nanoparticle formulation for HBV treatment, showing enhanced antiviral effects compared to free agonist in mice.

This paper shows ritonavir and other cytochrome P450 inhibitors reduce infectious HDV virion production by inducing oxidative stress and disrupting HBs glycoprotein biogenesis in human hepatocytes.

This study shows that HepaRG cells can be infected by HEV without DMSO treatment, making them a suitable model for studying HEV and its interaction with hepatocyte innate immunity.

This study identifies DYRK1A as a kinase that interacts with HBV cccDNA and enhances HBV RNA production by regulating the enhancer 1/X promoter.

This study identifies phosphorylation changes in host proteins induced by HBV infection in primary human hepatocytes, revealing an intrinsic anti-viral response involving DNA repair and RNA-binding proteins.